Page 4 - Astrazeneca

AstraZeneca admits Covishield has rare side effect: Is concern warranted?

AstraZeneca's acknowledgment that the vaccine may lead to thrombosis isn't a new revelation, but it underscores the need for transparent communication by the pharma companies, say experts

Covishield vaccine case: Plea filed in SC seeking probe on AstraZeneca

AstraZeneca, facing a lawsuit in UK for alleged vaccine-related deaths and injuries, has acknowledged that its vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS)

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Parents to sue Serum Institute over daughter's alleged Covishield death

Father says that AstraZeneca's admission of vaccine's rare side effect is 'too late'

AstraZeneca responds to Covishield vaccine concerns: Here's what they said

Regulatory agencies around the world maintain that the risks from the vaccine outweigh the benefits

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, cause TTS

AstraZeneca vaccine: From its origin to side effects, all you need to know

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?

Covishield, a vaccine developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India, can, in rare instances, lead to TTS

AstraZeneca admits its Covishield vaccine may lead to rare side effect

AstraZeneca has admitted for the first time in court documents that its Covid vaccine can cause rare side effects, marking an about-turn that may open the door for a multi-million pound legal payout

AstraZeneca trounces Q1 estimates as resilient demand fuels growth

AstraZeneca stuck by its forecast of total revenue and core earnings per share increasing by percentages in the low double-digits to low-teens in 2024

AstraZeneca bets on next-generation cancer therapy with $2 bn Fusion deal

AstraZeneca will pay $21 per Fusion share, a premium of more than 97% to the US-listed company's closing price on Monday

AstraZeneca, Mankind Pharma partner for distribution of asthma medication

Mankind Pharma, a pharmaceutical company in India, boasts a vast distribution network with over 16,000 field personnel and 13,000 stockists

AstraZeneca, Mankind Pharma sign pact to distribute asthma medicine

AstraZeneca Pharma India Ltd and Mankind Pharma Ltd on Monday said they have entered into an agreement for exclusive distribution of the Symbicort brand, an asthma medicine, in India. Symbicort is owned by AstraZeneca, which will retain the intellectual property rights and will continue to be the marketing authorisation holder (MAH) and import license after the agreement, a joint statement shared on BSE by AstraZeneca Pharma India said. "The partnership with Mankind Pharma presents an opportunity to accelerate access and maximise the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices," AstraZeneca India Managing Director and Country President Sanjeev Panchal said. Mankind Pharma has a distribution network, including close to 16,000 field forces and more than 13,000 stockists, across India providing access to quality pharmaceuticals across the country,

AstraZeneca to import critical drugs to India, focus on cancer therapies

AstraZeneca is currently conducting 50 clinical trials in India

AstraZeneca Pharma India to launch cancer drug Enhertu in January

Enhertu, an antibody-drug conjugate, is being used in the treatment of HER2-positive metastatic breast cancer in a number of countries globally

Drug major AstraZeneca commits $71 mn to Meghalaya's forestry project

European drug major AstraZeneca has announced a USD 71 million funding to plant and maintain an estimated 64 million plants and trees in the country, primarily in the ecologically fragile Meghalaya. The funding is part of its global forest programme, under which it has committed to plant 200 million trees across six continents by 2030, the company said in a statement on Monday. The company will implement the restoration programme in collaboration with Earthbanc, Earthtree, Worldview Impact India and the Hill Farmers Shiitake Mushroom Coop Society on the Meghalaya Reforestation and Sustainable Livelihoods Project called the Regeneration Meghalaya -- a 30-year regenerative horticulture and agriculture project in the northeastern state. About 200,000 trees have already been planted and with the official project launch, soil and water conservation work is underway to enable further planting of millions of trees in 2024. The project aims to help Meghalayan farmers restore 22,670 hectare

AstraZeneca Pharma India plans to sell its production plant in Bengaluru

AstraZeneca Pharma India plans to sell its production facility in Bengaluru as part of a strategic review of global manufacturing and supply network by its parent, according to a regulatory filing. The company remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes, AstraZeneca Pharma India said in a regulatory filing on Thursday. "As a part of AstraZeneca's ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course," it added. The company will position the manufacturing site for sale in a fully operational manner and begin a search for a buyer who can also act as a contract manufacturing organisation (CMO) for its products currently manufactured or packaged at the site, subject to receipt of necessary statutory approvals, the drug firm said. The company is fully .

Oxford-AstraZeneca covid vaccine faces legal challenge in UK: Report

The Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, is facing a legal challenge in the High Court in London, a UK media report said on Thursday. According to The Daily Telegraph', UK-based pharmaceutical giant AstraZeneca could face a number of further claims based on the outcome of test cases around the condition identified by specialists as Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT), believed to be related to the side effects of the COVID jab. AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects". "The fact of this legal battle poses a fundamental question: in circumstances where individuals are seriously injured or die because of a vaccination recommended by the government should the state provide access to adequate compensation,

Want to eliminate lung cancer as a cause of death: AstraZeneca India MD

The British drug major is developing next-generation vaccines that have the potential to generate potent and long-lasting immune responses

AstraZeneca sues US govt over Medicare drug price negotiation plans

The British drugmaker, which filed its complaint in a Delaware district court, joins other drugmakers and business groups claiming that the program would restrict the development of new medicines